Neurogen Corporation

Dorothy Gallager

Pamela Ann Albaugh

Kenneth Shaw

John Tallman

Geoffrey White

Marci Crandall

James Cassella

Lavanya Rajachandran

Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and ECof the compounds at defined series of cloned GABAsubtype receptors composed of specific variants of &#x3b1;, &#x3b2;, and &#x3b3; subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABAreceptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.

Methods for screening GABA-modulatory compounds for specified pharmacological activities

Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and EC of the compounds at defined series of cloned GABA subtype receptors composed of specific variants of &agr;,&bgr;, and &ggr; subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABA receptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.

Growing community of inventors

Columbus, MT, United States of America

Dorothy Gallager